Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen net Deferred Tax Liabilities Recognized on Balance Sheet ($M) ($M)
Form 10-Q / 10-K Consolidated Balance Sheets & Income Taxes Note (XBRL)
Latest, Q2 2026
1,301
Period ended Jun 30, 2026
Change on a year earlier
-6.1%
1,386 in Q2 2025
History
17 quarters
Since Q4 2019
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Deferred Tax Liabilities Recognized on Balance Sheet ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,301 | -6.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,344 | -11.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,366 | -15.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,458 | -14.8% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,386 | -22.1% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,510 | -18.9% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,616 | -31.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,711 | – | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,780 | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,862 | – | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,354 | +21,300.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q4 2022 | Dec 31, 2022 | 11 | -95.0% | Form 10-K (filed 2024-02-14) ↗ |
| Q4 2021 | Dec 31, 2021 | 219 | – | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 210 | – | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2020 | Jun 30, 2020 | 259 | – | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 427 | – | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 606 | – | Form 10-Q (filed 2020-05-01) ↗ |
Cite this data
StockData. (2026). Amgen Net Deferred Tax Liabilities Recognized on Balance Sheet ($M) ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/dtl_net_bs
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.